Literature DB >> 12782192

Effects of a selective agonist and antagonist of CRF2 receptors on cardiovascular function in the rat.

Kenneth B Mackay1, Theodore H Stiefel, Nick Ling, Alan C Foster.   

Abstract

The aim of the present study was to investigate the effects of activation or blockade of the CRF(2) receptor subtype on cardiovascular function in conscious rats following systemic i.v. administration of the CRF(2) receptor peptide agonist urocortin 2 given alone and the selective CRF(2) receptor peptide antagonist antisauvagine-30 given alone. Urocortin 2 caused a dose-dependent reduction in mean arterial blood pressure and a dose-dependent increase in heart rate. Pretreatment with antisauvagine-30 blocked the hypotensive effect of urocortin 2. Antisauvagine-30 failed to produce any statistically significant effects on mean arterial blood pressure and heart rate at doses that completely blocked the effects of urocortin 2. These data verify the cardiovascular effects of selective CRF(2) receptor activation, but find no evidence for an endogenous CRF(2)-mediated tone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12782192     DOI: 10.1016/s0014-2999(03)01725-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Facilitation of cardiac vagal activity by CRF-R1 antagonists during swim stress in rats.

Authors:  Susan K Wood; Robert E Verhoeven; Aaron Z Savit; Kenner C Rice; Peter S Fischbach; James H Woods
Journal:  Neuropsychopharmacology       Date:  2006-05-03       Impact factor: 7.853

2.  cAMP- and Ca²(+) /calmodulin-dependent protein kinases mediate inotropic, lusitropic and arrhythmogenic effects of urocortin 2 in mouse ventricular myocytes.

Authors:  Li-Zhen Yang; Jens Kockskämper; Shelina Khan; Jorge Suarez; Stefanie Walther; Bernhard Doleschal; Gregor Unterer; Mounir Khafaga; Heinrich Mächler; Frank R Heinzel; Wolfgang H Dillmann; Burkert Pieske; Joachim Spiess
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

3.  CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators.

Authors:  Katherine E Wiley; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2004-09-20       Impact factor: 8.739

4.  Corticotropin-releasing factor (CRF) receptor-1 is involved in cardiac noradrenergic activity observed during naloxone-precipitated morphine withdrawal.

Authors:  Elena Martínez-Laorden; Juan-Antonio García-Carmona; Alberto Baroja-Mazo; Paola Romecín; Noemí M Atucha; María-Victoria Milanés; María-Luisa Laorden
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

5.  The Modulation of Cardiac Contractile Function by the Pharmacological and Toxicological Effects of Urocortin2.

Authors:  Si Chen; Zhenhua Wang; Bo Xu; Xiangquan Mi; Wanqing Sun; Nanhu Quan; Lin Wang; Xingchi Chen; Quan Liu; Yang Zheng; Jiyan Leng; Ji Li
Journal:  Toxicol Sci       Date:  2015-09-04       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.